Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish company located in Dublin that manufactures and distributes pharmaceutical products. Salix Pharmaceuticals Ltd., now part of Bausch Health Cos., Inc. acquired Cosmo Technologies Ltd. from Cosmo Pharmaceuticals SA.\nThe company says this about itself: COSMO designs, manufactures and markets family-safe technology products. Committed to the idea that technology should be designed for families, not just repurposed from other segments, COSMO is pioneering new product categories. At the center of its offerings is its mobile application, COSMO: Mission Control. This hub for managing connected devices and family software is meant for families who are seeking a new way of doing technology.

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.

Peking University First Hospital is a company headquartered in Beijing, China and ultimately controlled by the Government of China. The firm operates as a hospital.

Immunovative Therapies is a biopharmaceutical company with financial support of the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. They specialize in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious disease.

Xinjiang Advance Glory Investment Co., Ltd., established on 2015-05-14, Business scope includes investment in the energy industry,agricultural investment,real estate investment,mining investment,business investment,Investment in education,tourism investment,Construction Industry Investment,Investment in environmental protection industry,Biotechnology R&D project investment,Realtor;food business;Health food sales;Food Internet Sales;food business(Selling prepackaged food);Food Internet Sales(Selling prepackaged food);liquor business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Proyecto de Biomedicina CIMA SL is a holding company engaged in the provision of product licensing and intellectual property rights management services. It holds patents generated by the Centro de Investigacion Medica Aplicada, which have indications across the clinical fields of oncology, hepatology, dermatology, and gene therapy. The company was founded in June 2003 and is headquartered in Pamplona, Spain.

Pujian Biological (Wuhan) Technology Co., Ltd., established on 2011-12-06, Business scope includes licensed projects:Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Research and development of bio-based materials technology;Biochemical product technology research and development;Fermentation process optimization technology research and development;R&D of industrial enzyme preparations;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Manufacturing of bio-based materials;Sales of bio-based materials;Natural science research and experimental development;Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Agricultural Science Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

VaxDesign, is a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures, and markets in vitro models of the human immune system. Its Modular IMmune In vitro Construct (MIMIC®) technology melds immunology with engineering to find elegant solutions to complex biological problems. The MIMIC® system was initially developed for the Rapid Vaccine Assessment Program of the U.S. Defense Advanced Research Projects Agency (DARPA) and has since been funded by several other U.S. federal agencies, such as the Defense Threat Reduction Agency, Biomedical Advanced Research and Development Authority, Army Chemical Biological Medical Systems (CBMS), and National Institute of Standards and Technology (NIST).

Shaanxi Tiancong Biotechnology Co., Ltd., established on 2016-01-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Feed Additive Sales;Information Technology Consulting Services;Chemical product sales(No licensed chemical products);software development;internet data service;Internet Security Services;Clothing and apparel retail;Big data service;luggage sales;Data processing and storage support services;Network and Information Security Software Development;Pet food and supplies retail;General merchandise sales;Clothing and apparel wholesale;Sales of building materials;Office Supplies Sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Feed additive production;Veterinary drug production;Veterinary drug business;Import and export;Technology Import and Export;Disinfectant production(Free of Hazardous Chemicals)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therepies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP

Stem Cell & Regenerative Medicine International, Inc. engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company is headquartered in Marborough, MA.

Tianjin Newsay Biotechnology Co., Ltd., established on 2014-04-23, Operating range includes cells,Nucleic acid and protein and other related biotechnology research,development and transfer;Biotechnology product development,technical consulting,Technical Services;Wholesale of Class I Medical Devices,retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Xinjiang Dingju Biotechnology Co., Ltd., established on 2014-05-07, Business scope includes biotechnology research and development,Technical exchange and promotion service,Quality inspection technical service,Medical equipment rental service,Medical Research and Experimental Development,Natural science research and experimental development,Biopharmaceutical Manufacturing,Trade Advisory Services,Business Information Consulting Service;Sales:Equipment,hardware products,electronic product;Chemical Products,Instrumentation,Glass product,ceramics,Medicine and Medical Equipment.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hengruiyuanzheng (Shanghai) Biotechnology Co., Ltd., established on 2015-07-08, Business scope includes licensed projects:pharmaceutical production;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:working in medical technology,Technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Engaged in the import and export of goods and technology,Re-export trade,Trade and trade agency between enterprises in the region,First,Class II medical device,electronic product,Equipment,Sales of metal materials and products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Hengruiyuanzheng (Shenzhen) Biotechnology Co., Ltd., established on 2015-07-22, Business scope includes general business items:working in medical technology,Technology development in the field of biotechnology,technical consulting;electronic product,Equipment,Sales of metal materials and products;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:one,two,3 Wholesale and sales of medical devices

Shanghai Cell Therapy Group Co. Ltd. is a Chinese company located in Shanghai that operates as a cell therapy company. The firm was founded in 2013 by Jie Wei Li.\nThe company says this about itself: Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of \"changing the length and abundance of life with cell therapy\", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

Shenzhen Hornetcorn Biotechnology Co., Ltd. principally engages in the research and development of immune cell therapy technology and the provision of immune cell therapy technology to medical institutions. The company was founded on November 29, 2010 and is headquartered in Shenzhen, China.